Objective To observe the therapeutic effect of Shensongyangxin capsule combined with metoprolol in the treatment of elderly patients with coronary heart disease and arrhythmia, as well the effect on blood lipid and blood pressure, the level of BNP.Methods From 2013 August to 2014 October, 132 cases of elderly patients with coronary heart disease and arrhythmia were randomly divided into observation group and control group, each group with 66 cases.2 groups of patients were given routine drug treatment, the control group was given metoprolol tartrate tablets tid, the initial dose was 25 mg, ad-justed the dosage according to the blood pressure levels and heart rate;in observation group, based on the theraphy as in the control group, also added with Shensongyangxin capsule, 1.2 g, tid.4 weeks as 1 course.Before and after treatment’ s the clinical curative effect and blood pressure (systolic blood pressure (SBP), diastolic blood pressure (DBP), blood lipid [tri glycerin (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol ( HDL-C) , brain natriuretic peptide ( BNP) ] changes were compared between the 2 groups of patients.Results After the treatment, the total effective rate of observation group was 89.4%, which was higher than that of the control group’s 71.2%(χ2 =10.469, P <0.05).After the treatment, ventricular contraction, atrial premature contraction, junctional contractions, paroxysmal atrial fibrillation significantly reduced ( P <0.05), and the observation group was significantly better than the control group ( P <0.05) ;after treatment, SBP, TC, TG, DBP, LDC-C and BNP level decreased significantly in both of the two groups, HDL-C increased significantly, and the observation group’ s blood pressure, blood lipids and the level of BNP was better than the control group ( P <0.05).Conclusion It proved that combining the Shensongyangxin capsule and meto-prolol in treatment of elderly patients with coronary heart disease combined with arrhythmia could effectively improve the level of blood lipid and blood pressure, BNP, it is worthy of clinical application.%目的：观察参松养心胶囊联合美托洛尔治疗老年冠心病心律失常患者的临床疗效及对血压、血脂和BNP水平的影响。方法选择2013年8月—2014年10月治疗的老年冠心病心律失常患者132例，按照随机数字表法分为观察组和对照组，每组66例。2组患者均给予常规药物治疗，对照组在常规治疗基础上给予酒石酸美托洛尔片3次／d，初始剂量为25 mg／次，根据患者的血压水平和心率变化情况调整剂量；观察组在对照组基础上加用参松养心胶囊，1．2 g／次，3次／d。均4周为1个疗程。观察2组患者治疗前后临床疗效以及血压[收缩压（ SBP）、舒张压（ DBP）]、血脂[三酰甘油（ TG）、总胆固醇（ TC）、低密度脂蛋白胆固醇（ LDL－C）、高密度脂蛋白胆固醇（ HDL－C）]、脑钠肽（BNP）变化情况。结果治疗后观察组总有效率为89．4％，高于对照组的71．2％（χ2＝10．469， P﹤0．05）。治疗后室性期前收缩、房性期前收缩、交界性期前收缩、短阵心房颤动发生次数均明显减少（ P ＜0．05），且观察组显著优于对照组（ P﹤0．05）；治疗后2组患者SBP、DBP、TC、TG、LDC－C及BNP水平显著降低，HDL－C明显提高，且观察组血压、血脂及BNP水平改善情况明显优于对照组（ P﹤0．05）。结论参松养心胶囊和美托洛尔联合治疗老年冠心病心律失常患者疗效确切，可有效改善患者的血压、血脂及BNP水平，值得临床推广应用。
展开▼
